BiotechTube

GC012F Injection infusion

Phase 1Recruiting
0 views this week 0 watching💤 Quiet
Interest: 36/100
36
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Idiopathic Inflammatory Myopathy (IIM)

Conditions

Idiopathic Inflammatory Myopathy (IIM)

Trial Timeline

Sep 15, 2025 → Sep 15, 2029

NCT ID
NCT07086404

About GC012F Injection infusion

GC012F Injection infusion is a phase 1 stage product being developed by AstraZeneca for Idiopathic Inflammatory Myopathy (IIM). The current trial status is recruiting. This product is registered under clinical trial identifier NCT07086404. Target conditions include Idiopathic Inflammatory Myopathy (IIM).

What happened to similar drugs?

20 of 20 similar drugs in Idiopathic Inflammatory Myopathy (IIM) were approved

Approved (20) Terminated (1) Active (0)
✅Tirzepatide + Tirzepatide PlaceboEli LillyApproved
✅Levodopa-carbidopa intestinal gel (LCIG)AbbVieApproved
✅Carvedilol + Metoprolol succinate + Metoprolol succinate + doxazosinAstraZenecaApproved
✅Omalizumab + PlacebosNovartisApproved
✅Nintedanib + PirfenidoneRocheApproved
✅Tocilizumab + NSAIDs + CSs + MTXRocheApproved
✅TocilizumabRocheApproved

Hype Score Breakdown

Clinical
6
Activity
15
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT07086404Phase 1Recruiting

Competing Products

20 competing products in Idiopathic Inflammatory Myopathy (IIM)

See all competitors
ProductCompanyStageHype Score
Lubiprostone + Lubiprostone + PlaceboDr. Reddy's LaboratoriesPhase 3
37
KPL-716 + PlaceboKiniksa PharmaceuticalsPhase 2
29
Caveolin-1-Scaffolding-Protein-Derived Peptide (LTI-03) + PlaceboRein TherapeuticsPhase 1
19
LTI-03 + PlaceboRein TherapeuticsPhase 1
19
LTI-03 + PlaceboRein TherapeuticsPhase 2
32
Tirzepatide + Tirzepatide PlaceboEli LillyApproved
50
MRA(Tocilizumab)Chugai PharmaceuticalPhase 3
40
MRA(Tocilizumab) + placeboChugai PharmaceuticalPhase 3
40
MRA(Tocilizumab)Chugai PharmaceuticalPhase 3
40
MRA(Tocilizumab)Chugai PharmaceuticalPhase 3
40
Zimura + EyleaAstellas PharmaPhase 2
27
Avacincaptad PegolAstellas PharmaPhase 2
35
Rituximab + cyclosporineSun PharmaceuticalPhase 3
32
E5501EisaiPhase 1
29
E5501 + Drug: E5501EisaiPhase 1
29
E5501 40 mg 2 x 20-mg tablets, orally, fasted + E5501 40 mg 2 x 20-mg tablets, orally, with food + E5501 40mg 2 x 20-mg tablets, orally, fasted + E5501 40 mg 2 x 20-mg tablets, orally, with foodEisaiPhase 1
29
Eltrombopag + Avatrombopag + Standard of careEisaiPhase 3
32
Placebo + Avatrombopag tabletsEisaiPhase 2
35
PerampanelEisaiPre-clinical
26
Blinded (placebo) + Open Label (Avatrombopag tablets) + Blinded (Avatrombopoag tablets)EisaiPhase 2
35